Inco Intelligence has launched a specific drug for rare diseases designed by AI, which has launched human clinical trials in China and the United States at the same time.

CTOnews.com June 28 news, New York and Hong Kong as dual headquarters of the start-up Insilico Medicine (Insilico Medicine) yesterday released news that its new drug designed through AI has started in China and the United States to verify its efficacy of phase II clinical trials.

▲ The drug treats a rare disease called idiopathic pulmonary fibrosis (IPF) and will be tested in clinical trials for 60 people at 40 institutions in China and the United States.

IPF is a chronic progressive fibrosis interstitial pneumonia of unknown origin. The incidence rate is about 2-10 cases per 100,000 people in various countries. At present, the number of patients in the world has reached 3 - 5 million. No effective drug has been found before.

Inco Intelligence used AI to analyze a large amount of medical data, found the protein structure associated with the development and development of IPF, and screened out substances that inhibit the action of the protein. With the help of AI, this work has drastically reduced costs and time investment.

Yingke Intelligence said that since 2021, the company has discovered 12 new drug candidates for liver cancer, breast cancer and other diseases using this technology, and is conducting relevant animal trials, three of which have entered clinical trials for humans.

IncoSmart's investors include Fosun International of China and Warburg Pincus of the United States. The company received US $60 million in financing in June last year (CTOnews.com Note: currently about 433 million yuan). At present, the company has signed technology licensing agreements with large pharmaceutical companies such as Sanofi of France and Johnson & Johnson of the United States.